Cargando…

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry

Detalles Bibliográficos
Autores principales:	Miravitlles, Marc, Turner, Alice M., Torres-Duran, María, Tanash, Hanan, Rodríguez-García, Carlota, López-Campos, José Luis, Chlumsky, Jan, Guimaraes, Catarina, Rodríguez-Hermosa, Juan Luis, Corsico, Angelo, Martinez-González, Cristina, Hernández-Pérez, José María, Bustamante, Ana, Parr, David G., Casas-Maldonado, Francisco, Hecimovic, Ana, Janssens, Wim, Lara, Beatriz, Barrecheguren, Miriam, González, Cruz, Stolk, Jan, Esquinas, Cristina, Clarenbach, Christian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938555/ https://www.ncbi.nlm.nih.gov/pubmed/36800958 http://dx.doi.org/10.1186/s12931-023-02340-6

Ejemplares similares

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Demographic and clinical characteristics of patients with α(1)-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO
por: Torres-Durán, María, et al.
Publicado: (2022)

Protocol for the EARCO Registry: a pan-European observational study in patients with α(1)-antitrypsin deficiency
por: Greulich, Timm, et al.
Publicado: (2020)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Research priorities in α(1)-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration
por: Barrecheguren, Miriam, et al.
Publicado: (2020)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group
por: Greulich, Timm, et al.
Publicado: (2022)

Practice and knowledge about diagnosis and treatment of alpha-1 antitrypsin deficiency in Spain and Portugal
por: Esquinas, Cristina, et al.
Publicado: (2016)

Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency
por: Pons, Mònica, et al.
Publicado: (2021)

Diagnosis of alpha-1 antitrypsin deficiency: a population-based study
por: Barrecheguren, Miriam, et al.
Publicado: (2016)

New variants of alpha-1-antitrypsin: structural simulations and clinical expression
por: Gonzalez, Angel, et al.
Publicado: (2022)

Application of a diagnostic algorithm for the rare deficient variant Mmalton of alpha-1-antitrypsin deficiency: a new approach
por: Belmonte, Irene, et al.
Publicado: (2016)

Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study
por: Calle Rubio, Myriam, et al.
Publicado: (2018)

Correction: Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study
por: Calle Rubio, Myriam, et al.
Publicado: (2019)

Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT)
por: Esquinas, Cristina, et al.
Publicado: (2018)

Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
por: Núñez, Alexa, et al.
Publicado: (2021)

Correction to: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
por: Núñez, Alexa, et al.
Publicado: (2021)

Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency
por: Esquinas, Cristina, et al.
Publicado: (2017)

Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory
por: Belmonte, Irene, et al.
Publicado: (2020)

Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study
por: Rodríguez Hermosa, Juan Luis, et al.
Publicado: (2023)

Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin
por: Torres-Durán, María, et al.
Publicado: (2023)

COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients
por: Calle Rubio, Myriam, et al.
Publicado: (2023)

Regional lung densities in alpha-1 antitrypsin deficiency compared to predicted values
por: Stoel, Berend C., et al.
Publicado: (2019)

Long-term effect of α(1)-antitrypsin augmentation therapy on the decline of FEV(1) in deficient patients: an analysis of the AIR database
por: Schouten, Iris G.M., et al.
Publicado: (2021)

Alpha-1 antitrypsin deficiency: outstanding questions and future directions
por: Torres-Durán, María, et al.
Publicado: (2018)

Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire
por: Núñez, Alexa, et al.
Publicado: (2018)

Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update
por: Blanco, Ignacio, et al.
Publicado: (2017)

Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide
por: Blanco, Ignacio, et al.
Publicado: (2017)

Is SARS-COV-2 associated with alpha-1 antitrypsin deficiency?
por: Rodríguez-García, Carlota, et al.
Publicado: (2023)

Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
por: Tanash, Hanan A, et al.
Publicado: (2010)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

Hereditary alpha-1-antitrypsin deficiency and its clinical consequences
por: Fregonese, Laura, et al.
Publicado: (2008)

Estimated Prevalence and Number of PiMZ Genotypes of Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide
por: Martinez-González, Cristina, et al.
Publicado: (2021)

Liver disease in adults with severe alpha-1-antitrypsin deficiency
por: Tanash, Hanan A., et al.
Publicado: (2019)

Determinants in the Underdiagnosis of COPD in Spain—CONOCEPOC Study
por: Calle Rubio, Myriam, et al.
Publicado: (2022)

Smoking and COPD Knowledge in the General Spanish Population: A CONOCEPOC Study
por: Rodríguez Hermosa, Juan Luis, et al.
Publicado: (2023)

Alpha(1)-antitrypsin deficiency: current perspective on research, diagnosis, and management
por: Stolk, Jan, et al.
Publicado: (2006)

Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics
por: Ramon, Maria A, et al.
Publicado: (2017)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

What have we learned from observational studies and clinical trials of mild to moderate COPD?
por: Barrecheguren, Miriam, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g3eeqv37qs2o0129va1jpjfsta